AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 287: H435-H446, 2004; doi:10.1152/ajpheart.00262.2004
0363-6135/04 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (41)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiffrin, E. L.
Right arrow Articles by Touyz, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiffrin, E. L.
Right arrow Articles by Touyz, R. M.

SPECIAL MEDICAL EDITORIAL

From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension

Ernesto L. Schiffrin1,2 and Rhian M. Touyz1

1Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension and Hypertension Clinic, Clinical Research Institute of Montréal; and 2Division of Internal Medicine, Department of Medicine, University of Montréal Hospital Centre, Montréal, Québec, Canada H2W 1R7

RESISTANCE ARTERIES are vessels of ~100–300 µm in lumen diameter that are an important site of resistance to blood flow. Small artery-dependent increased peripheral resistance may participate in development and complications of hypertension. The degree of remodeling of small arteries has prognostic significance over a 10-yr period, with worse prognosis for hypertensive subjects with greater remodeling. In almost all hypertensive subjects, a reduction in lumen and an increase in the media-to-lumen ratio are found, without increase in its media cross section, as a result of rearrangement of smooth muscle cells and increased collagen and fibronectin. Approximately 60% of hypertensive patients exhibit endothelial dysfunction already in stage 1 hypertension. Study of human vascular smooth muscle cells and of vessels from experimental animals has demonstrated that ANG II, aldosterone, and endothelin exert remodeling effects in large measure by activation of NADPH oxidase, and to lesser degree by stimulating xanthine oxidase and mitochondrial reactive oxygen species generation. Stimulation of angiotensin type 1 (AT1) receptors (AT1R) leads to increased reactive oxygen species in part via activation of nonreceptor tyrosine kinases such as c-src, and of PKC and phospholipase D, and thereby contributes to endothelial dysfunction by inactivating nitric oxide (NO). Treatment of hypertensive patients with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, but not {beta}-blockers, corrects small artery structure and endothelial dysfunction, which may favorably affect outcome in the long term, beyond the 3–5 yr of randomized clinical trials during which most antihypertensives affect outcome similarly as long as blood pressure is well controlled.

RESISTANCE ARTERIES IN HYPERTENSION: FROM CLINIC TO LABORATORY

A major objective of translational research from bench to bedside is to test in humans novel therapeutic modalities developed through experimentation. However, because our understanding of many human diseases, such as hypertension, is still very limited, there is a critical need for bedside to bench research. We and other researchers have demonstrated that in human hypertension, resistance arteries undergo remodeling and altered reactivity. What remains uncertain, however, is how these processes occur and whether they are primary causative events or secondary adaptive phenomena. To answer some of these questions, it is imperative to extend bedside observations and findings to the bench, where molecular and cellular processes underlying vascular changes in hypertension can be studied in isolated vessels and cells in in vitro conditions. Ideally, one would like to examine cells directly involved in the pathological process under investigation. In hypertension, this includes vascular smooth muscle cells in resistance arteries. However, because of ethical and practical constraints, this is not always possible, and most studies investigating subcellular processes in hypertension are conducted, in large part, in cells from animal models, where hypertension is spontaneous or induced experimentally. When human cells are examined, they are usually derived from large arteries and veins obtained during surgery, from postmortem specimens, or from immortalized cell lines. Because these conditions do not control for blood pressure status and other variables of subjects from whom the cells are derived, it is inordinately difficult to extrapolate findings from such cell models to what may be happening in vascular cells during the development of hypertension. Because circulating blood cells are easily accessible from humans, many investigators have studied cellular events and signaling cascades in platelets, erythrocytes, and leukocytes as markers of events in vascular cells. However, this model is suboptimal because circulating cells are devoid of a supporting extracellular matrix and adventitia and have very different morphological and functional phenotypes compared with vascular smooth muscle cells.

Over the past 10 yr, we successfully developed a system for the study of isolated vessels and vascular smooth muscle cells derived from human small arteries obtained from gluteal biopsies of subcutaneous tissue. This unique approach provides multiple benefits. First, small arteries and vascular cells derived from these are obtained from healthy individuals and well-characterized hypertensive patients, with or without treatment. Second, the vascular smooth muscle cells are derived from resistance arteries, which contribute to blood pressure regulation, elevation of peripheral resistance and development of hypertension. Third, low-passaged cells that maintain their morphological and functional properties are studied. With the use of this approach, implementing "bedside to bench" research is realized, gaining a fuller understanding of cellular processes and signaling pathways contributing to vascular remodeling in hypertension. Our long-term goal is to identify putative genes and/or proteins fundamentally involved in hypertensive vascular pathology that could be used as targets for manipulation in the prevention and management of human hypertension. Ultimately and ideally, our findings will echo back from "bench to bedside" to test novel therapeutic strategies developed through experimentation. We will recapitulate our own scientific itinerary from the bedside and studies of human small artery remodeling to the bench and the use of cells derived from these human small arteries as well as cells from vessels from experimental animals, and with the insights gained in the latter, back to the bedside, with studies of the action of agents that block these mechanisms, in particular the inhibitors of the renin-angiotensin system, and their effect on vascular remodeling in hypertensive humans.

STRUCTURAL CHANGES IN RESISTANCE ARTERIES IN HUMAN ESSENTIAL HYPERTENSION

Increased peripheral resistance is the hallmark of essential hypertension (94) (Fig. 1). Increased peripheral resistance results primarily from the increased energy dissipation that occurs when blood flows through small resistance arteries with reduced lumen. Resistance arteries have a lumen of 100–300 µm (11) and play an important role in the development of hypertension (136). Small artery remodeling may also lead to complications of hypertension (137), including myocardial ischemia (13, 61, 78), stroke (22), and renal failure (79). Recently it was demonstrated that increased media-to-lumen ratio is associated with increased cardiovascular events over a 10-yr period of follow-up of 150 subjects, which included normotensive controls, essential hypertensive individuals, and subjects with hyperaldosteronism, pheochromocytoma, renovascular hypertension, and diabetes (124).



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1. Blood pressure is the product of cardiac output and total peripheral resistance. In general, increased peripheral resistance is the major factor contributing to elevated pressure in essential hypertension. Flow diagram demonstrates vascular mechanisms contributing to increased peripheral resistance, a hallmark of hypertension. Vasoactive agents, mechanical factors and oxidative stress interact to influence vascular structure and function. ANG II, angiotensin II; ET-1, endothelin-1; {uparrow}, increase; –, no change.

 
Resistance arteries from normotensive and hypertensive patients, and from persons with diabetes and dyslipidemia, have been mainly investigated by obtaining biopsies of gluteal subcutaneous tissue, followed by dissection of small arteries. This technique, which was first introduced by Heagerty and Mulvany (1), is invasive but well tolerated and allows studies of well-characterized hypertensive subjects, individuals with dyslipidemia, and persons with diabetes, etc. The first finding with this technique has been that in essential hypertension small arteries do not exhibit hypertrophy, but rather "eutrophic remodeling" (62, 107, 140144, 146), in which the outer diameter and lumen of these vessels are smaller, the media-to-lumen ratio is greater, but the cross-sectional area of the media is not different from that of age and sex-matched normotensive subjects (62, 107, 142). The increased media-to-lumen ratio (105, 143, 144) is the most reproducible parameter in longitudinal and cross-sectional studies (135). In small arteries from patients with essential hypertension there does not appear to be any smooth muscle cell hypertrophy or hyperplasia in the media (81) whereas there may be in secondary hypertension (125–127). Smooth muscle cells are rearranged around a smaller lumen, and this is accompanied by increased extracellular matrix deposition (71, 72, 74). The restructuring of smooth muscle cells may be the result of increased vasoconstriction (6) or of increased apoptosis in the periphery of the vessel with enhanced growth toward the lumen (73) and could also entail motility changes in smooth muscle cells contributing to this cellular rearrangement. Recently, we found that whereas structural remodeling of small arteries is found in all hypertensive patients, impairment of endothelial function is found in ~60% and left ventricular hypertrophy in 45% of hypertensive patients (115) with stage I hypertension (according to the recent Joint National Committee VII classification) (21). We have concluded that altered structure of small arteries may be the first manifestation of target organ damage in hypertensive humans before the appearance of microalbuminuria, thickening of the intima media of the carotid arteries, or development of cardiac hypertrophy. It still remains to be established whether remodeling of resistance arteries precedes the development of hypertension or is a consequence of elevated blood pressure. In patients with severe hypertension, secondary hypertension, and in acromegalic patients (103, 122, 125127), small arteries undergo hypertrophic remodeling, where media growth encroaches on the lumen to increase the media-to-lumen ratio and media cross-sectional area.

Role of ANG II in Vascular Structural Changes in Hypertension

Vascular smooth muscle cells are dynamic, multifunctional cells that contribute to arterial remodeling through numerous processes, including cell growth (hyperplasia and hypertrophy), apoptosis, elongation of cells, reorganization of cells and/or altered extracellular matrix composition (8, 52, 72, 81, 125, 127) (Fig. 2). Hyperplasia refers to an increase in vascular smooth muscle cell number associated with DNA synthesis and is stimulated by ANG II (55, 127, 130). Hypertrophy, a reversible process, refers to increased cell size due to increased protein synthesis and/or increased intracellular cell water volume (68). ANG II stimulates hypertrophy by stimulating protein synthesis and by inducing activation of transmembrane transport systems, which influence transmembrane movement of ions and water. In experimental models of hypertension, hyperplasia, and hypertrophy have been demonstrated to contribute, to varying degrees, to vascular remodeling (3, 32, 106, 153). We demonstrated that ANG II stimulates both hyperplasia and hypertrophy and that in human vascular smooth muscle cells from resistance arteries of essential hypertensive patients, these growth responses are enhanced (175, 176).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2. Molecular and cellular mechanisms whereby ANG II influences vascular structure in hypertension. ANG II binds to the ANG type 1 (AT1) receptor (AT1R), leading to activation of receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR) and insulin-like growth factor-1 receptor (IGF-1R), and nonreceptor tyrosine kinases, such as c-Src. In addition, ANG II:AT1R binding induces activation of NAD(P)H oxidase resulting in intracellular generation of reactive oxygen species (ROS), which influence redox-sensitive signaling molecules, such as mitogen-activated protein (MAP) kinases (p38MAP kinase, JNK, ERK1/2, and ERK5), transcription factors [NF-{kappa}B, AP-1, and hypoxia-inducible factor (HIF-1)] and matrix metalloproteinases (MMP). ANG II may downregulate (indicated by minus sign) peroxisome proliferator-activated receptors (PPARs), which have anti-inflammatory effects, thus enhancing vascular inflammation. These signaling events regulate vascular smooth muscle cell growth, extracellular matrix (ECM) protein production and inflammatory responses. Under pathological conditions, altered ANG II signaling leads to altered growth, fibrosis, and inflammation, which contribute to structural remodeling in hypertension. PAI, plasminogen activator inhibitor; RXR, retinoid X receptor.

 
In eutrophic remodeling, characteristic of vessels in mild essential hypertension, apoptosis and vascular fibrosis may also be important (72–74). Apoptosis, gene-regulated cell death, is involved in the fine tuning of media growth and is increased in some vascular beds (36, 151) and decreased in others (31) in hypertensive rats. The exact role of apoptosis in arterial remodeling remains unclear, and it is unknown whether apoptosis is a growth-associated compensatory and adaptive process or a primary event. However, an imbalance between growth and apoptosis could be important (128, 190). Many studies (27, 151, 166) have suggested that ACE inhibitors and AT1R blockers could contribute to regression of vascular wall growth through activation of proapoptotic pathways. Apoptosis may also play a role in microvascular rarefaction, which has been implicated in the development of hypertension (56). Furthermore, there is evidence that detachment of vascular smooth muscle cells and endothelial cells (anoikis) may also contribute to vascular dysfunction and remodeling in hypertension (98, 159).

Vascular fibrosis involves the accumulation of extracellular matrix proteins, such as collagen, elastin, fibrillin, fibronectin, and proteoglycans, in the vascular media. Increased collagen deposition in the vascular media has been demonstrated in experimental hypertension and in subcutaneous resistance arteries from essential hypertensive patients (74, 120, 130, 164). Increased collagen I and III mRNA and enhanced collagen protein synthesis by fibroblasts have also been demonstrated in patients with essential hypertension (28). Experimental studies indicate that collagen accumulation may be related, in part, to increased ANG II-stimulated synthesis (43, 130, 177). In addition to inducing production, ANG II regulates collagen degradation by attenuating interstitial matrix metalloproteinase (MMP) activity and by enhancing tissue inhibitor of metalloproteinase-1 production (16, 189). A similar role may be played by endothelin-1 in blood vessels and the heart (4). In patients with untreated hypertension, serum levels of MMP-1 (88) and MMP-9 (91) have been reduced with normalization after 1 yr of lisinopril treatment (88). These data further support a role for ANG II in profibrotic processes in human hypertension.

Increasingly it has been appreciated that evidence of an inflammatory reaction may be recorded in association with the hypertensive process (7, 17, 73, 91, 165). It is unclear whether angiotensin II, endothelin-1, or aldosterone, agents that participate in the pathophysiology of hypertension and that induce inflammation in the heart, the vasculature, and the kidney (12, 82, 129, 171, 193) or blood pressure elevation by itself, through effects on adhesion molecules, chemokines, or endothelin-1 induced by cyclic mechanical strain (18, 195, 201) are associated with the inflammatory response that is found in hypertension. As well, the intriguing possibility that inflammation may activate the renin-angiotensin system and contribute to vascular remodeling and hypertension has been raised (194). Recently, it has been demonstrated that the activators of nuclear receptors, such as the peroxisome proliferator-activated receptors (PPARs), that are well-known hypolipidemic agents (the fibrates, PPAR {alpha}-agonists), or insulin sensitizers (glitazones, PPAR-{gamma} agonists), downregulate the cardiac (37) and vascular inflammatory response in experimental animals (34, 35, 69) and serum markers of inflammation in humans (60). Furthermore, these inflammatory markers have been found to predict the risk of developing hypertension (42, 150). Chronic subclinical inflammation has been associated with the insulin resistance syndrome (45) that may precede the development of hypertension (57). Thus PPARs and vasoactive substances may be endogenous modulators of the inflammatory process that plays a role in structural changes that occur in the vasculature in hypertension, and inflammation may contribute to accelerate vascular damage in cardiovascular disease including hypertension. In fact, ANG II has been shown to downregulate PPARs, an effect mediated through activation of NF-{kappa}B (167). Blockade of the action of these agents or activation of PPARs may contribute to slow down cardiovascular damage in hypertension.

Vascular inflammation is characterized by recruitment of monocytes and lymphocytes into the subendothelial space, production of chemotactic cytokines, increased expression of adhesion molecules, reactive smooth muscle cell proliferation, and altered extracellular matrix production and degradation. These processes, together with lipid oxidation, are proatherogenic, particularly in damaged arteries in hypertension. ANG II has significant proinflammatory actions in the vascular wall, inducing the production of reactive oxygen species, such as superoxide (O2–·) and H2O2, cytokines, adhesion molecules, and activation of redox-sensitive inflammatory genes (156). Vascular O2–· and H2O2 function intracellularly as second messengers, influencing redox-sensitive signaling molecules that regulate vascular smooth muscle cell contraction/dilation, cell growth (hypertrophy and hyperplasia), apoptosis, and extracellular matrix protein content (172, 191, 203). ANG II also modulates expression of proinflammatory molecules in the vessel wall, such as VCAM-1, ICAM, and E-selectin expression through redox-dependent pathways (23, 82, 119). In vascular smooth muscle cells, ANG II stimulates VCAM-1 production, chemokine monocyte chemotactic protein-1, and the cytokine IL-6 (116), which stimulate the recruitment of mononuclear leukocytes into the vessel media. Many of these factors are increased in plasma from hypertensive patients and it has been suggested that elevated circulating levels of cytokines and chemokines may reflect vascular inflammation and target organ damage in hypertensive patients (66, 96). To support the role of endogenous ANG II in vascular inflammation, AT1R blockers have been shown to reduce serum levels of VCAM-1, TNF-{alpha}, and O2–· in patients with early atherosclerosis (110).

FUNCTIONAL ABNORMALITIES OF RESISTANCE ARTERIES IN HYPERTENSION

Enhanced myogenic tone has been reported in experimental hypertension (76), and it has been suggested that this is a primary event in hypertension that may lead to the chronic vascular changes described above. Most vasoconstrictor agents such as endothelin-1 and vasopressin as well as norepinephrine appear to elicit normal or diminished constrictor responses in clinical hypertension (1, 62, 141, 142). Whether there is amplification of vasoconstrictor responses by the structural or mechanical reduction of lumen diameter according to the law of Laplace (47, 48, 80, 199, 200) is controversial (75). However, ANG II appears to frequently elicit enhanced vasoconstrictor responses in essential hypertension (142). This effect may be direct or indirect through increased sympathetic activity (29, 117). Enhanced ANG II-induced vascular contraction is attributed to increased cytoplasmic free Ca2+ concentration ([Ca2+]i) and is probably due to postreceptor signaling changes (179, 180) (Fig. 3). Recent studies (20) demonstrate that increased sensitivity of the contractile machinery through RhoA/Rho kinase-dependent pathways may also contribute to increased vascular contractility in hypertension.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3. Molecular and cellular mechanisms whereby ANG II influences vascular function in hypertension. ANG II increases intracellular free Ca2+ concentration ([Ca2+]i) by stimulating Ca2+ influx and through mobilization from sarcoplasmic reticular (SR) stores, the latter in response to inositol 1,4,5-trisphosphate produced by activation of PLC. Increased activity of the RhoA/Rho kinase Ca2+-sensitizing pathway and PKC-dependent pathways (dashed line) also influence contractility. ANG II-induced NAD(P)H oxidase-mediated generation of superoxide (O2·) quenches endothelial-derived nitric oxide (NO), resulting in decreased cGMP production and increased peroxynitrite (ONOO–) formation, with consequently altered vasodilation. In hypertension, altered ANG II signaling leads to increased contraction, decreased dilation, and increased vascular tone. DAG, diacylglycerol; MLC, myosin light chain; GEF, guanine nucleotide exchange factor; p, phosphorylated; G, G protein; {uparrow}, increase; {downarrow}, decrease.

 
The endothelium is critically involved in modulating vascular relaxation through release of endothelial-derived NO, stimulation of vascular smooth muscle cell soluble guanylate cyclase, and the subsequent increase in intracellular cGMP. Altered vascular tone in hypertension is associated with impaired endothelium-dependent vasodilation due, in large part, to reduced NO signaling (44, 85, 104). Endothelial dysfunction has been demonstrated in vessels from hypertensive humans (30, 113, 114) and in many experimental models of hypertension (30, 33, 92, 92, 95) but is also found with aging (84, 104), diabetes, dyslipidemia, obesity, smoking, hyperhomocysteinemia, and other conditions in the absence of elevated blood pressure (139). Impaired endothelial function may result from reduced generation of NO due to reduced expression/abundance of endothelial NO synthase (eNOS) or decreased activation of eNOS, and increases in oxidative stress that reduce the bioavailability of NO through conversion to peroxynitrate (14, 100, 185). Increased concentrations of asymmetric dimethylarginine that inhibit NOS may be a mechanism for reduced production of NO in hypertension (10, 26). Oxidant stress may also lead to reduction in tetrahydrobiopterin, which induces the uncoupling of NOS, which then produces O2–· rather than NO (86). Enhanced production of the vasoconstrictor peptide endothelin-1 is another mechanism whereby abnormal endothelial function may contribute to vasospasm, blood pressure elevation and complications of hypertension (reviewed in Ref. 138). Increased generation of arachidonic acid-derived products with vasoconstrictor properties (endothelium-derived contracting factors) is another manifestation of endothelial dysfunction (30, 33). Alterations in vasodilator mechanisms have been identified also in endothelial-independent systems. Although the endothelium was considered the major regulator of vascular relaxation through the NO/cGMP pathway, recent experimental evidence indicates that endothelium-independent processes also play a role in vascular tone modulation (93). However, there is little convincing data to support these findings in human hypertension. Clinical studies demonstrate, for the most part, that vasodilatory responses to acetylcholine (endothelium dependent) but not to sodium nitroprusside (endothelium independent) are attenuated in human hypertension (113, 140). Furthermore, only endothelium-dependent relaxation seems to be positively influenced by antihypertensive therapy. Hence, the clinical significance of experimental hypertensive models exhibiting impaired endothelium-independent dilation awaits clarification.

ANG II Signaling in Human Vascular Smooth Muscle Cells and in Experimental Animals

Angiotensin receptors. The many actions of ANG II are mediated via specific, highly complex intracellular signaling pathways that are stimulated after initial binding of the peptide to its cell-surface receptors. Two major receptor subtypes have been cloned and characterized, AT1R and AT2R (70, 108, 155, 180). In humans, AT1R is widely expressed and is located in numerous tissues, including the blood vessels, heart, kidney, adrenal glands, and liver. In contrast, AT2R is present primarily in fetal tissue, decreasing rapidly after birth, with relatively low amounts normally expressed in adult tissue (67). In pathological conditions associated with cardiac and vascular remodeling or inflammation, AT2R expression is upregulated (15). Both receptors play a role in the regulation of vascular smooth muscle, although they differ in their action. Whereas the AT1R is associated with growth, inflammation and vasoconstriction, the AT2R is associated, in general, with apoptosis and vasodilation (64, 158, 169). Recent data (2, 89) suggest that AT2R may also exert hypertrophic and proinflammatory effects, but this awaits further clarification.

Growth signaling by ANG II in vascular smooth muscle cells. Although ANG II is classically described as a vasoconstrictor agent, it is now clear that this hormone has potent growth, proinflammatory and profibrotic actions. Like growth factors, ANG II induces cell hyperplasia and hypertrophy by stimulating phosphorylation of tyrosine kinases, activation of mitogen-activated protein (MAP) kinases, mobilization of intracellular Ca2+ and production of reactive oxygen species (134, 183). ANG II binding to AT1R induces phosphorylation of multiple tyrosine kinases, including c-Src, JAK, focal adhesion kinase (FAK), Pyk2, p130Cas and phosphatidylinositol 3-kinase (40, 183). Findings from our laboratory in human vascular smooth muscle cells identified c-Src as one of the kinases immediately phosphorylated in response to ANG II, and involved not only in trophic effects but also in smooth muscle cell contraction (182). Furthermore, we showed that ANG II-induced activation of c-Src is augmented and that this is associated with increased growth in cells from hypertensive patients (178). c-Src is a major regulator of many distal targets, including PLC-{gamma}, Pyk2, FAK, JAK, Shc, MAP kinases, phosphatidylinositol 3-kinase, and NAD(P)H oxidase (50, 59, 180). These proteins influence cell survival, metabolism, cytoskeletal reorganization and membrane trafficking and have been identified as having important growth promoting and anti-apoptotic actions (49, 132).

Of the many growth-signaling pathways, the MAP kinase family is best characterized (163). In vascular smooth muscle cells ANG II activates all four of the major MAP kinases, including ERK1/2, p38 MAP kinase, c-Jun NH2-terminal kinases (JNK) and ERK5 (83, 99, 202). ERK1/2, phosphorylated by MEK1/2 (MAP/ERK kinase), is a key growth signaling kinase, whereas JNK and p38 MAP kinase, phosphorylated by MEK4/7 and MEK3/6, respectively, influence cell survival, apoptosis, differentiation and inflammation. ERK5, a redox-sensitive MAP kinase, is involved in protein synthesis, cell cycle progression and cell growth. In cardiac, renal, and vascular tissue from hypertensive rats and vascular smooth muscle cells from hypertensive patients, ANG II-stimulated activation of tyrosine kinases, ERK1/2, JNK, and p38MAP kinase is augmented (51, 197). These processes have been associated with enhanced vascular smooth muscle cell growth, inflammation, fibrosis, as well as increased vascular contractility.

ANG II can also activate receptor tyrosine kinases, even though it may not bind directly to these receptors. This process of transactivation has been demonstrated for EGF receptor, PDGF receptor, subtype {beta}, and IGF-1 receptor (131, 174). Processes underlying ANG II-induced receptor tyrosine kinase transactivation include activation of tyrosine kinases (Pyk2 and Src), redox-sensitive processes and possibly mulation of MMPs that release heparin-binding EGF (131, 174, 187). ANG II also increases production of vasoactive hormones and growth factors in hypertension, such as ET-1, PDGF, TGF{beta}, basic FGF, and IGF-1, which could promote cell proliferation, protein synthesis, and fibrosis, further contributing to growth processes in arterial remodeling.

ANG II signaling through reactive oxygen species in vascular smooth muscle cells. Growing evidence indicates that ANG II mediates many of its cellular actions by stimulating formation of intracellular reactive oxygen species, which are highly reactive, bioactive, short-lived molecules that derive from a reduction of molecular oxygen (162). Reactive oxygen species participate in numerous biological processes by acting as second messengers to modulate the activation of various signaling molecules and pathways (46, 87). ANG II increases production of reactive oxygen species in all types of vascular cells, including endothelial cells, smooth muscle cells, and adventitial fibroblasts (87, 90, 112).

A major source of oxygen intermediates in the vascular wall is ANG II-modulated nonphagocytic NAD(P)H oxidase, which is upregulated in hypertension (188, 196). Neutrophil NAD(P)H oxidase is the prototype oxidase and comprises five subunits, gp91phox (Nox2), p22phox, p47phox, p67phox, and p40phox, all of which have been detected, to varying degrees, in vascular cells (25). Studies in rat vascular smooth muscle cells indicate that gp91phox is replaced by the homologues Nox1 and Nox4 (157, 160). However, in vascular smooth muscle cells from human resistance arteries we demonstrated that gp91phox is the major Nox isoform present (173). These differences may be important functionally because Nox1 has been implicated to be involved in cell growth, Nox4 in delayed cell growth and gp91phox may act as a proton pump in addition to being part of the NAD(P)H oxidase complex (65, 97, 157, 160, 173). Whereas ANG II upregulates Nox1 and gp91phox, it downregulates Nox4 (160, 173). Moreover whereas gp91phox is primarily cell membrane-associated, Nox1 localizes in caveolae and Nox4 in focal adhesion. Thus these findings reflect important differences between human and rat cells and highlight the fact that caution should be applied when extrapolating results from animal studies to humans.

O2–· and H2O2 activate multiple signaling molecules, including MAP kinases (p38 MAP kinase, JNK, ERK-5, and ERK1/2), nonreceptor tyrosine kinases (Src, JAK2, STAT, p21Ras, Pyk2, and Akt), receptor tyrosine kinases (EGFR, IGFR, and PDGFR), protein tyrosine phosphatases and redox-sensitive transcription factors (NF-{kappa}B, AP-1, and HIF-1) (109, 170). Activation of these molecules participates in cell growth, migration, expression of proinflammatory genes, production of extracellular matrix proteins and contraction (39). All of these processes play important roles in vascular remodeling in hypertension. Exact mechanisms whereby reactive oxygen species modify signaling molecules remain unclear, but oxidative modification of proteins is important (19, 77).

ANG II-mediated activation of NAD(P)H oxidase involves c-Src, PKC, PLA2, and PLD as well as increased synthesis of gp91phox, p22phox, p47phox and p67phox (53, 175, 184). In hypertension, these processes are augmented, contributing to increased activation of the oxidase and consequent oxidative stress (181). Furthermore, various polymorphisms in the promoter of the p22(phox) gene have been identified in hypertensive patients, which may also play a role in increased NAD(P)H-driven generation of O2–· in hypertension (101).

Inhibition of NAD(P)H oxidase activity is now being considered, at least experimentally, as a possible therapeutic target in the treatment of hypertension (41). In fact, it has been suggested that some of the beneficial actions of ACE inhibitors and AT1 receptor antagonists may be mediated, in part, by decreasing vascular oxidative stress. These effects have been attributed to direct inhibition of NAD(P)H oxidase activity, as shown for AT1 receptor blockers, and to intrinsic antioxidant properties of the agents. Recent clinical studies support a direct antioxidant effect of AT1 receptor blockers, since treatment of hypertensive patients with candesartan reduced oxidative stress and inflammation independently of blood pressure-lowering actions (38).

EFFECT OF RENIN-ANGIOTENSIN BLOCKADE ON SMALL ARTERIES IN HUMAN HYPERTENSION

As indicated earlier, we have attempted to go from the bedside to the bench to elucidate some of the mechanisms involved in the regulation of the vasculature and its abnormalities in essential hypertension, eventually to come back to the bedside to determine whether indeed interfering with those mechanisms could improve the vascular status of patients and eventually their outcome. Accordingly, we have taken the agents that interfere with these mechanisms and used them on patients, and questioned whether the use of these drugs would correct the remodeling of the vasculature of hypertensive patients. We treated hypertensive patients in double-blind randomized studies for 1 (143) or 2 yr (144, 145) with the ACE inhibitor cilazapril compared with the {beta}-blocker atenolol. The ACE inhibitor corrected the structure and improved the endothelial function of small gluteal subcutaneous arteries whereas the {beta}-blocker had no effect despite equal blood pressure control. Thybo et al. (168) obtained similar results with the ACE inhibitor perindopril compared with atenolol for 1 yr. Rizzoni et al. (121) examined hypertensive subjects treated with lisinopril for 3 yr, and found that the media-to-lumen ratio was slightly reduced, and endothelial function slightly improved. We also investigated treatment with the angiotensin receptor blocker (ARB) losartan, again compared with atenolol (146). The ARB normalized the structure of small arteries and the endothelial dysfunction, whereas again the atenolol-treated group had no change (146). More recently, we evaluated the effect of switching patients who had been randomized to treatment with atenolol to the ARB irbesartan (147). Under atenolol use for 1 yr, the structure and function of small arteries had remained abnormal; however, 1 yr after the patient was switched to the ARB and achieved equal blood pressure control, structure and endothelial function were normalized.

Blockade of ANG II-induced oxidative stress and its growth-promoting, profibrotic and proinflammatory action may also play a role in correction of remodeling and endothelial dysfunction. ARBs increase circulating ANG II, which may stimulate unblocked AT2R, which could contribute to the improved structure and function (15). Vasodilation may also play a role, as vasoconstriction has been shown to induce inward eutrophic remodeling (6). Blood pressure reduction does not seem to contribute because atenolol-treated patients had their blood pressure was equally well controlled but exhibited no improvement. A recent study (111) has suggested that {beta}-adrenergic receptors in smooth muscle cells inhibit cell growth and collagen production. {beta}-Blockade could exacerbate the latter and antagonize any beneficial effect of lowering of blood pressure.

It should, however, be clarified that whereas {beta}-blockers, or at least atenolol, do not seem to improve vascular remodeling or endothelial dysfunction, they have other beneficial properties in hypertension, particularly in relation to cardioprotection through their anti-ischemic effects, as they reduce oxygen consumption by the heart. For this reason, although atenolol was not shown to be vasculoprotective, {beta}-blockers are indeed indicated as the first choice of therapy in patients with hypertension, and are a compelling indication in those with ischemic heart disease unless there are specific contraindications such as asthma, severe peripheral vascular disease, bradycardia, or atrioventricular block (21). Even though in the Atherosclerosis Risk in Community study (58) {beta}-blockers were found to have induced de novo diabetes mellitus to greater degree than other antihypertensive agents, in the UK Prospective Diabetes Study (186), atenolol was shown to be equally efficacious as the angiotensin-converting enzyme (ACE) inhibitor captopril, in preventing cardiovascular events. However, this aspect of UK Prospective Diabetes Study has been criticized as being underpowered to find differences between these individual agents. Most trials have been unable to detect differences between antihypertensive agents to prevent cardiovascular events, as discussed below.

Relevance of Regression of Small Artery Remodeling in Hypertensive Humans

The changes that are demonstrated in subcutaneous resistance arteries are similar to those found in experimental animals in the heart, kidney, and brain. We have shown that endothelial function of small arteries from gluteal subcutaneous biopsies correlates closely with endothelium-dependent brachial artery flow-mediated dilatation (114), which in turn correlates with coronary vasomotion (5). Coronary vasomotion has been shown to relate to cardiovascular outcome (133). The structure of small arteries dissected from gluteal subcutaneous tissue correlates with coronary flow (123) and with the type of cardiac remodeling present (103, 122). The media-to-lumen ratio of small arteries was greater in patients with dilated cardiac hypertrophy, which has poor prognosis. The same group demonstrated that patients with a greater media-to-lumen ratio of small arteries suffer more cardiovascular events (124). Treatment with the ACE inhibitors enalapril (102) and perindopril (149) has been shown to improve coronary reserve, and perindopril also diminished pericoronary fibrosis in small vessels in hypertensive subjects (149). The calcium channel blockers nifedipine gastrointestinal transport system (192) or lacidipine (161) improved forearm blood flow responses to acetylcholine, agreeing with findings in small arteries from gluteal subcutaneous biopsies (140, 148, 152). These different results demonstrate the pathophysiological relevance of gluteal subcutaneous small arteries, which appear to be good surrogates for more critical vascular beds.

Numerous meta-analyses of randomized clinical trials (9, 154), and the recent Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (54) and Second Australian National Blood Pressure studies (198) demonstrate that most agents reduce cardiovascular events largely to a similar degree as long as blood pressure is adequately controlled. This could suggest that whether agents do or do not have vasculoprotective effects, the results of treatment are similar. However, it should be recalled that most randomized clinical trials last 3–5 yr. The study of Rizzoni et al. (124) suggests that divergence of survival without events between individuals with greater or lesser degree of remodeling of small arteries occurs after 3–4 yr. Furthermore, the Heart Outcomes Prevention Evaluation study (63) supported the idea that ACE inhibitors protect from cardiovascular events beyond blood pressure lowering, although in the Perindopril Protection Against Recurrent Stroke Study (118) blood pressure lowering seemed to play a very important role in secondary stroke prevention, and even in the Heart Outcomes Prevention Evaluation, blood pressure lowering may have had a critical role. The recent Losartan Intervention for Endpoint study (24) has suggested that ARBs are superior to {beta}-blockers, and this trial is the one that most favors the hypothesis of beneficial effects of vascular protection beyond blood pressure lowering. Thus it is possible that benefits of vascular protection are found after long-term treatment and may not be demonstrable within the period of time (3–5 yr) that most randomized clinical trials take place.

GRANTS

This study was supported by Canadian Institutes of Health Research Grants 13570, 37917, and 44018, and a group grant from the Multidisciplinary Research Group on Hypertension.

DISCLOSURES

The authors have financial interests (research grants, consultancies, and honoraria) from Bayer, Bristol-Myers Squibb, Hoffmann-LaRoche, Merck-Frosst, and Pfizer.

FOOTNOTES


Address for reprint requests and other correspondence: E. L. Schiffrin, Clinical Research Institute of Montreal, 110 Pine Ave. W., Montreal, Quebec, Canada H2W 1R7 (E-mail: ernesto.schiffrin{at}ircm.qc.ca).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

REFERENCES

  1. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, and Mulvany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 61: 181–186, 1987.[Abstract/Free Full Text]
  2. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, Ouchi Y, and Dzau VJ. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2: 13–20, 2000.[Abstract/Free Full Text]
  3. Amann K, Gharehbaghi H, Stephen S, and Mall G. Hypertrophy and hyperplasia of smooth muscle cells of small intramyocardial arteries in spontaneously hypertensive rats. Hypertension 25: 124–131, 1995.[Abstract/Free Full Text]
  4. Ammarguellat FZ, Gannon PO, Amiri F, and Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension 39: 679–684, 2002.[Abstract/Free Full Text]
  5. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, and Yeung AC. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26: 1235–1241, 1995.[Abstract]
  6. Bakker ENTP, Van der Meulen ET, Van den Berg BM, Everts V, Spaan JAE, and VanBavel E. Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J Vasc Res 39: 12–20, 2002.[CrossRef][ISI][Medline]
  7. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, and Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 19: 857–861, 2001.[CrossRef][ISI][Medline]
  8. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 81: 999–1030, 2001.[Abstract/Free Full Text]
  9. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535, 2003.[CrossRef][ISI][Medline]
  10. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, and Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1847, 1998.
  11. Bohlen HG. Localization of vascular resistance changes during hypertension. Hypertension 8: 181–183, 1986.[Free Full Text]
  12. Brasier AR, Recinos A III, and Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22: 1257–1266, 2002.[Abstract/Free Full Text]
  13. Brush JEJ, Cannon RO, Schenke WH, Bonow RO, Leon MB, Maron BJ, and Epstein SE. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 319: 1302–1307, 1988.[Abstract]
  14. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 87: 840–844, 2000.[Abstract/Free Full Text]
  15. Carey RM, Lin XH, and Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 14: 98S-102S, 2001.[CrossRef][ISI][Medline]
  16. Castoldi G, Di Gioia CRT, Pieruzzi F, D'Orlando C, Van de Greef WMM, Busca G, Sperti G, and Stella A. ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo. Am J Physiol Heart Circ Physiol 284: H635–H643, 2003.[Abstract/Free Full Text]
  17. Chae CU, Lee RT, Rifai N, and Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 38: 399–403, 2001.[Abstract/Free Full Text]
  18. Chen JX, Fabry B, Schiffrin EL, and Wang N. Twisting integrin receptors increases endothelin-1 gene expression in endothelial cells. Am J Physiol Cell Physiol 280: C1475–C1484, 2001.[Abstract/Free Full Text]
  19. Chiarugi P and Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 28: 509–514, 2003.[CrossRef][ISI][Medline]
  20. Chitaley K, Weber D, and Webb RC. RhoA/Rho-kinase, vascular changes, and hypertension. Curr Hypertens Rep 3: 139–144, 2001.[Medline]
  21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, and Roccella EJ. National Heart Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee and National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560–2572, 2003.[Abstract/Free Full Text]
  22. Collins R, Peto F, and MacMahon S. Blood pressure, stroke, and coronary heart disease, part 2: short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335: 827–838, 1990.[CrossRef][ISI][Medline]
  23. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, and Puri PL. Endothelial activation by angiotensin II through NF{kappa}B and p38 pathways: involvement of NF{kappa}B-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 195: 402–410, 2003.[CrossRef][ISI][Medline]
  24. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, and The LS Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003, 2002.[CrossRef][ISI][Medline]
  25. Dang PM, Cross AR, Quinn MT, and Babior BM. Assembly of the neutrophil respiratory burst oxidase: a direct interaction between p67Phox and cytochrome b558 II. Proc Natl Acad Sci USA 99: 4262–4265, 2002.[Abstract/Free Full Text]
  26. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, and Cooke JP. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108: 3042–3047, 2003.[Abstract/Free Full Text]
  27. DeBlois D, Orlov SN, and Hamet P. Apoptosis in cardiovascular remodeling–effect of medication. Cardiovasc Drugs Ther 15: 539–545, 2001.[CrossRef][ISI][Medline]
  28. Delva P, Lechi A, Pastori C, Degan M, Sheiban I, Montesi G, Pea M, Meneguzzi A, and Menegazzi M. Collagen I and III mRNA gene expression and cell growth potential of skin fibroblasts in patients with essential hypertension. J Hypertens 20: 1393–1399, 2002.[CrossRef][ISI][Medline]
  29. Dendorfer A, Thornagel A, Raasch W, Grisk O, Tempel K, and Dominiak P. Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension 40: 348–354, 2002.[Abstract/Free Full Text]
  30. Deng LY, Li JS, and Schiffrin EL. Endothelium-dependent relaxation of small arteries from essential hypertensive patients: mechanisms and comparison with normotensive subjects and with responses of vessels from spontaneously hypertensive rats. Clin Sci (Lond) 88: 611–622, 1995.[Medline]
  31. Dickhout JG and Lee RM. Apoptosis in the muscular arteries from young spontaneously hypertensive rats. J Hypertens 17: 1413–1419, 1999.[CrossRef][ISI][Medline]
  32. Dickhout JG and Lee RM. Structural and functional analysis of small arteries from young spontaneously hypertensive rats. Hypertension 29: 781–789, 1997.[Abstract/Free Full Text]
  33. Diedrich DA, Yang Z, Buhler FR, and Luscher TF. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve the cyclooxygenase pathway. Am J Physiol Heart Circ Physiol 258: H445–H451, 1990.[Abstract/Free Full Text]
  34. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, and Schiffrin EL. PPAR{alpha} activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 40: 866–871, 2002.[Abstract/Free Full Text]
  35. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, and Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats. Role of peroxisome proliferator-activated receptor-{gamma}. Circulation 105: 2296–2302, 2002.[Abstract/Free Full Text]
  36. Diep QN, Li JS, and Schiffrin EL. In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension 34: 617–624, 1999.[Abstract/Free Full Text]
  37. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, and Schiffrin EL. PPAR-{alpha} activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. Mol Cell Cardiol 36: 295–304, 2004.[CrossRef][ISI][Medline]
  38. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, and Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 26: 691–697, 2003.[CrossRef][ISI][Medline]
  39. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95, 2002.[Abstract/Free Full Text]
  40. Eguchi S and Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept 91: 13–20, 2000.[CrossRef][ISI][Medline]
  41. Elmarakby AA, Williams JM, and Pollock DM. Targeting sources of superoxide and increasing nitric oxide bioavailability in hypertension. Curr Opin Investig Drugs 4: 282–290, 2003.[Medline]
  42. Engstrom G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, and Lindgarde F. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 22: 2054–2058, 2002.[Abstract/Free Full Text]
  43. Eto H, Biro S, Miyata M, Kaieda H, Obata H, Kihara T, Orihara K, and Tei C. Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury. Cardiovasc Res 59: 200–211, 2003.[Abstract/Free Full Text]
  44. Feldman RD and Gros R. Impaired vasodilator function in hypertension. The role of alterations in receptor-G protein coupling. Trends Cardiovasc Med 8: 297–305, 1998.[CrossRef][ISI][Medline]
  45. Festa A, D'Agostino RJ, Howard G, Mykkanen L, Tracy RP, and Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42–47, 2000.[Abstract/Free Full Text]
  46. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 15: 247–254, 2003.[CrossRef][ISI][Medline]
  47. Folkow B. Hypertensive structural changes in systemic precapillary resistance vessels: How important are they for in vivo haemodynamics. J Hypertens 13: 1546–1559, 1995.[ISI][Medline]
  48. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 62: 347–504, 1982.[Free Full Text]
  49. Force T and Bonventre JV. Growth factors and mitogen activated protein kinases. Hypertension 31: 152–161, 1998.[Abstract/Free Full Text]
  50. Frame MC, Fincham VJ, Carragher NO, and Wyke JA. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 3: 233–245, 2002.[CrossRef][ISI][Medline]
  51. Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, and Motley ED. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology 141: 3120–3126, 2000.[Abstract/Free Full Text]
  52. Fukuda N. Molecular mechanisms of the exaggerated growth of vascular smooth muscle cells in hypertension. J Atheroscler Thromb 4: 65–72, 1997.[Medline]
  53. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG, De Leon H, Wilcox JN, and Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45–51, 1997.[Abstract/Free Full Text]
  54. Furberg CD, Wright JT Jr, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F, Oparil S, Probstfield J, Whelton P, Nwachuku C, Gordon D, Proschan M, Einhorn P, Ford CE, Piller LB, Dunn JK, Goff D, Pressel S, Bettencourt J, and DeLeon B. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997, 2002.[Abstract/Free Full Text]
  55. Gibbons GH, Pratt RE, and Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-{beta}1 expression determines growth response to angiotensin II. J Clin Invest 90: 456–461, 1992.[ISI][Medline]
  56. Gobe G, Browning J, Howard T, Hogg N, Winterford C, and Cross R. Apoptosis occurs in endothelial cells during hypertension-induced microvascular rarefaction. J Struct Biol 118: 63–72, 1997.[CrossRef][ISI][Medline]
  57. Goff DC Jr, Zaccaro DJ, Haffner SM, and Saad MF. Insulin sensitivity and the risk of incident hypertension. Insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 26: 805–809, 2003.[Abstract/Free Full Text]
  58. Gress TW, Nieto FJ, Shahar E, Wofford MR, and Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study [see comment]. N Engl J Med 342: 905–912, 2000.[Abstract/Free Full Text]
  59. Haendeler J, Yin G, Hojo Y, Saito Y, Melaragno M, Yan C, Sharma VK, Heller M, Aebersold R, and Berk BC. GIT1 mediates Src-dependent activation of phospholipase Cgamma by angiotensin II and epidermal growth factor. J Biol Chem 278: 49936–49944, 2003.[Abstract/Free Full Text]
  60. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, and Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679–684, 2002.[Abstract/Free Full Text]
  61. Hasdai D, Gibbons RJ, Holmes DRJ, Higano ST, and Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 96: 3390–3395, 1997.[Abstract/Free Full Text]
  62. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, and Mulvany MJ. Small artery structure in hypertension: dual processes of remodeling and growth. Hypertension 21: 391–397, 1993.[Free Full Text]
  63. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253–259, 2000.[CrossRef][ISI][Medline]
  64. Henrion D, Kubis N, and Lévy BI. Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin. II. From large arteries to the microcirculation. Hypertension 38: 1150–1157, 2001.[Abstract/Free Full Text]
  65. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, and Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 00: 00–00, 2003.
  66. Hlubocka Z, Umnerova V, Heller S, Peleska J, Jindra A, Jachymova M, Kvasnicka J, Horky K, and Aschermann M. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 16: 557–562, 2002.[CrossRef][ISI][Medline]
  67. Horiuchi M, Akishita M, and Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613–621, 1999.[Abstract/Free Full Text]
  68. Hu WY, Fukuda N, and Kanmatsuse K. Growth characteristics, angiotensin II generation, and microarray-determined gene expression in vascular smooth muscle cells from young spontaneously hypertensive rats. J Hypertens 20: 1323–1333, 2002.[CrossRef][ISI][Medline]
  69. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, and Schiffrin EL. Effect of peroxisome proliferator-activated receptor-{alpha} and -{gamma} activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23: 45–51, 2003.[Abstract/Free Full Text]
  70. Inagami T, Yamano Y, Bardhan S, Chaki S, Guo DF, Ohyama K, Kambayashi Y, Takahashi K, Ichiki T, Tsuzuki S, and Tang H. Cloning, expression and regulation of angiotensin II receptors. Adv Exp Med Biol 377: 311–317, 1995.[Medline]
  71. Intengan HD, Deng LY, Li JS, and Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 33: 569–574, 1999.[Abstract/Free Full Text]
  72. Intengan HD and Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36: 312–318, 2000.[Abstract/Free Full Text]
  73. Intengan HD and Schiffrin EL. Vascular remodeling in hypertension. Roles of apoptosis, inflammation, and fibrosis. Hypertension 38: 581–587, 2001.[Abstract/Free Full Text]
  74. Intengan HD, Thibault G, Li JS, and Schiffrin EL. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats. Effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 100: 2267–2275, 1999.[Abstract/Free Full Text]
  75. Izzard AS, Bund SJ, and Heagerty AM. Increased wall-lumen ratio of mesenteric vessels from the spontaneously hypertensive rat is not associated with increased contractility under isobaric conditions. Hypertension 28: 604–608, 1996.[Abstract/Free Full Text]
  76. Izzard AS and Heagerty AM. Impaired flow-dependent dilatation in distal mesenteric arteries from the spontaneously hypertensive rat. J Physiol 518: 239–245, 1999.[Abstract/Free Full Text]
  77. Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim Biophys Acta 1604: 77–94, 2003.[Medline]
  78. Kinlay S, Selwyn AP, Libby P, and Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol 32: S62–S66, 1998.[CrossRef][ISI][Medline]
  79. Klahr S and Morrissey J. Progression of chronic renal disease. Am J Kidney Dis 41: S3–S7, 2003.[ISI][Medline]
  80. Korner PI, Angus JA, and Wright CE. Structure and the resistance amplifier in hypertension: reply to the dissenters. J Hypertens 18: 235–239, 2000.[CrossRef][ISI][Medline]
  81. Korsgaard N, Aalkjær C, Heagerty AM, Izzard AS, and Mulvany MJ. Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 22: 523–526, 1993.[Abstract/Free Full Text]
  82. Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, and Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19: 1623–1629, 1999.[Abstract/Free Full Text]
  83. Kubo T, Ibusuki T, Chiba S, Kambe T, and Fukumori R. Altered mitogen-activated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 29: 537–543, 2002.[CrossRef][ISI][Medline]
  84. Kung CF and Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 25: 194–200, 1995.[Abstract/Free Full Text]
  85. Lamping K. Interactions between NO and cAMP in the regulation of vascular tone. Arterioscler Thromb Vasc Biol 21: 729–730, 2001.[Free Full Text]
  86. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, and Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201–1209, 2003.[CrossRef][ISI][Medline]
  87. Lassègue B and Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285: R277–R297, 2003.[Abstract/Free Full Text]
  88. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, and Díez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98: 535–540, 1998.[Abstract/Free Full Text]
  89. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109: 8–13, 2004.[Free Full Text]
  90. Li JM and Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 278: 12094–12100, 2003.[Abstract/Free Full Text]
  91. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, and Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75: 43–47, 2000.[CrossRef][ISI][Medline]
  92. Lockette W, Otsuka Y, and Carretero O. The loss of endothelium-dependent vascular relaxation in hypertension. Hypert 8, SupplII: II-61–II-66, 1986.
  93. Lopez-Farre A, Rodriguez-Feo JA, Garcia-Colis E, Gomez J, Lopez-Blaya A, Fortes J, de Andres R, Rico L, and Casado S. Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the {alpha}1-receptor blocker doxazosin. J Hypertens 20: 463–470, 2002.[CrossRef][ISI][Medline]
  94. Lund-Johansen P. Haemodynamics in early essential hypertension–still an area of controversy. J Hypertens 1: 209–213, 1983.[CrossRef][Medline]
  95. Luscher TF and Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 8: 344–348, 1986.[Abstract/Free Full Text]
  96. Malmqvist K, Wallén HN, Held C, and Kahan T. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 20: 1563–1569, 2002.[CrossRef][ISI][Medline]
  97. Maturana A, Krause KH, and Demaurex N. NOX family NADPH oxidases: do they have built-in proton channels? J Gen Physiol 120: 781–786, 2002.[Free Full Text]
  98. Meilhac O, Ho-Tin-Noe B, Houard X, Philippe M, Michel JB, and Angles-Cano E. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J 17: 1301–1303, 2003.[Abstract/Free Full Text]
  99. Meloche S, Landry J, Huot J, Houle F, Marceau F, and Giasson E. P38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol Heart Circ Physiol 279: H741–H751, 2000.[Abstract/Free Full Text]
  100. Mitchell BM, Dorrance AM, Ergul A, and Webb RC. Sepiapterin decreases vasorelaxation in nitric oxide synthase inhibition-induced hypertension. J Cardiovasc Pharmacol 43: 93–98, 2004.[ISI][Medline]
  101. Moreno MU, San José G, Orbe J, Páramo JA, Beloqui O, Díez J, and Zalba G. Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. FEBS Lett 542: 27–31, 2003.[CrossRef][ISI][Medline]
  102. Motz W and Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 27: 1031–1038, 1996.[Abstract/Free Full Text]
  103. Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D, Castellano M, Garavelli G, and Agabiti-Rosei E. Structural chan